C
ardiovascular disease is the leading cause of morbidity and mortality in the United States, 1 and acute myocardial infarction (MI) accounts for a significant proportion of the disease burden of cardiovascular disease. Advances in prevention and treatment strategies have led to significant improvement in clinical outcomes and age-adjusted mortality from MI. 2 It remains unclear, though, whether similar progress has been achieved in outcomes that are particularly patient centric, such as the ability to maintain or return to employment.
Social determinants of health are strongly linked to the risk of human disease, with employment, or the lack thereof, being one of the most significant. 3 The risk of MI increases linearly with each cumulative job loss. 3 Single-center studies performed in the early percutaneous coronary intervention (PCI) era have shown that more than a third of patients with MI are unable to return to work by 1 year. 4, 5 Job loss significantly interacts with other psychosocial factors, such as depression and health status; for example, depression can be both a cause and a consequence of an adverse change in employment. 6 Employment status may also influence medication-taking behavior and affordability. 7 However, the prevalence of adverse change in employment after MI and the association between post-MI job changes and psychosocial outcomes and medicationtaking behavior have not been well investigated in a large representative US cohort.
Using data from the TRANSLATE-ACS registry (Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome), 8 we assessed the prevalence of adverse change in employment between baseline and 1-year post-MI in a national US cohort. We compared patient-reported depression, quality of life, medication adherence, and financial hardship affording medications between patients who experienced an adverse change in employment and those who remained working at 1 year without an adverse change.
METHODS

Study Population
TRANSLATE-ACS is a longitudinal, observational registry of patients treated for acute MI at 2333 US hospitals between April 2010 and October 2012. Details of the design and conduct of the TRANSLATE-ACS study have been previously published. 8 (Data Supplement) Patients were included in the registry if they were ≥18 years of age presenting with ST-segment-elevation myocardial infarction (STEMI) or non-STEMI, treated with PCI and a P2Y12 inhibitor, were not enrolled in another research study, and were able to provide written consent for longitudinal telephonic follow-up and data collection. Study enrollment received institutional review board approval at each participating hospital. Of the total 12 365 patients enrolled in 233 US hospitals, we excluded patients who died in-hospital (n=14), did not have baseline (n=98), and 1-year employment status recorded (n=2934), resulting in a final study population of 9319 patients for this analysis.
Data Collection and Definitions
Detailed demographic, clinical, and angiographic characteristics, in-hospital laboratory values, and adverse outcomes (as shown in Table 1 ) were collected for all patients using a standardized set of data elements and definitions in accordance with those used by the National Cardiovascular Data Registry CathPCI Registry. 9 Centralized telephone follow-up was conducted by trained Duke Clinical Research Institute personnel for all enrolled patients at 6 weeks and 6, 12, and 15 months after discharge. At each interview, standardized questionnaires collected interval medication changes and patientreported outcomes using validated instruments, as described in the Outcomes section below. 10, 11 Patients were asked about their work status at the 1-year interview. Those who reported working full-time or part-time were defined as working. We defined an adverse change in employment as patients who reported working immediately before the index MI hospitalization but were either no longer working or working fewer hours 1 year later. Patients no longer working at 1 year included those who report being laid off, disabled, on sick leave, retired, or unemployed for other or nonspecified reasons.
Hospital bills were collected for all subsequent hospital visits involving at least 1 overnight stay, including inpatient or observation status admission. 12 Medical records were collected to permit independent physician adjudication of recurrent MI, coronary revascularization procedures, stroke, and bleeding events occurring within 1-year post-MI. Unplanned readmissions were defined as any bill-confirmed hospital visit
WHAT IS KNOWN
• Clinical outcomes of acute myocardial infarction have experienced sustained improvement during the past several decades.
• Acute myocardial infarction, historically, has had a profoundly adverse experience on patients' ability to resume full employment.
WHAT THE STUDY ADDS
• In a more contemporary national US population, adverse change in employment only affects 1 in 10 patients after acute myocardial infarction.
• Bleeding after cardiac catheterization and unplanned rehospitalization are the factors most strongly associated with adverse change in employment after acute myocardial infarction.
• Patients who experience adverse change in employment have worse health status, depression, and hardship affording medications than patients who do not experience adverse change in employment.
involving at least 1 overnight stay except for hospitalizations involving an adjudicated, planned coronary revascularization within 60 days of the index PCI.
Outcomes
Outcomes of interest included depression, self-rated health status, evidence-based medication (EBM) persistence, 13 patient-reported medication adherence, 14 and financial hardship associated with medication costs. 12 Depression and selfrated health status at baseline, 6 weeks, 6 months, and 1-year post-MI were compared between patients with and without adverse change in employment. Depression was defined as a Patient Health Questionnaire (PHQ) score-2 >3, 15 and health status was measured using the EuroQoL-5 Dimensions (EQ5D) visual analog scale (VAS). 11 As previously described, persistence was defined as percentage of patients still taking the EBMs prescribed at discharge at the 1-year interview. 13 These EBMs included aspirin, P2Y12 inhibitors, statins, β-blockers, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. Consistent with prior work, patientreported medication adherence was a summed score based on 3 questions asked during the 1-year interview 14 ; the score ranged from 0 to 3 where 0 indicates optimal adherence: (1) do you sometimes forget heart medications? yes=1, no=0; (2) how often do you have difficulty remembering to take all your heart medications? never=0, all other answers=1; and (3) do you know what to do if you run out of medication? yes=0, no=1. Patients were asked to rank on a scale of 1 to 5 the financial hardship of their monthly medication cost (1=no hardship, 2=minimal hardship, 3=moderate hardship, 4=much hardship, 5=extreme hardship). Financial hardship was defined as a score >2.
Statistical Analysis
We compared patient characteristics between patients working at baseline and not working at baseline, and then among those working at baseline, those with and without an adverse change in employment by 1 year. Categorical variables were presented as frequencies (percentages), and differences between the groups were assessed using the χ 2 test. Continuous variables are presented as mean with SD and were compared using the Wilcoxon rank-sum test. Changes in depression and EQ5D VAS over time were compared among patients who experienced adverse change in employment, patients who retained employment, and patients who were not employed or retired at baseline. We calculated P trends for changes in EQ5D VAS and PHQ2 >3 over time from baseline to 6 months to 1-year post-MI.
We used logistic regression to assess factors associated with adverse change in employment status at 1-year postdischarge. The variable list, adapted from prior research based on clinical judgment, 4, [16] [17] [18] included the following variables: age, sex, race, Hispanic ethnicity, insurance status, education level, marital status, diabetes mellitus, hypertension, smoking, body mass index, prior MI, prior PCI, prior coronary artery bypass graft surgery, prior stroke/transient ischemic attack, peripheral arterial disease, atrial fibrillation/flutter, chronic lung disease, STEMI, multivessel disease, multivessel PCI, creatinine clearance, ejection fraction ≤40%, length of index stay, presentation or in-hospital development of heart failure signs/ symptoms, cardiac arrest, cardiogenic shock, baseline PHQ2 >3, baseline EQ5D VAS, postdischarge events within 1 year (recurrent MI, unplanned revascularization, stroke, Bleeding Academic Research Consortium 2+ bleeding), and number of all-cause unplanned rehospitalizations. We used generalized estimating equations with exchangeable correlation structure to account for within-hospital clustering. We calculated a C-index to assess how well this model discriminated between patients with and without an adverse change in employment.
We used a similar methodology to assess the association of adverse change in employment with 1-year depression, EBM persistence, medication adherence, and financial hardship affording medications. Each model adjusted for the following variables: age, sex, race, body mass index, STEMI, prior MI, diabetes mellitus, hypertension, smoker, number of unplanned rehospitalizations in first year, Bleeding Academic Research Consortium 2+ bleeding in first year, number of meds reported at 1 year (of aspirin, P2Y12 inhibitor, statin, β-blocker, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers), baseline EQ5D VAS, and baseline PHQ2. Adjusting for these same variables, we assessed the association of adverse change in employment with 1-year EQ5D VAS using linear regression with generalized estimating equations.
Variables inputted into the model were missing <5%. To account for missing data, categorical variables were imputed to the mode, creatinine clearance, and ejection fraction was imputed using medians, and body mass index was imputed using sex and STEMI versus non-STEMI-specific medians. We did not impute clinical outcomes. In all instances, P<0.05 was considered statistically significant. All analyses were performed with SAS version 9.2 (Cary, NC).
RESULTS
In the final study population of 9319 patients, the mean age was 55.8 years (SD, 9.2) and 27.3% were women; more than half (n=4730; 51%) were working at the time of their index MI (Figure 1 ). Patients not working at baseline were more likely to be older, black, women, unmarried, and not have graduated high school (Table 1) . They were more likely to have medical comorbidities than patients who were working. Most patients not working at baseline were retired (n=3355; 73%). Patients working at baseline were more likely to smoke and to present with STEMI or have a cardiac arrest during the index MI hospitalization.
Changes in Work Status
Among patients working at baseline, 10% (n=492) reported an adverse change in employment 1 year later, with 7% (n=349) no longer working whereas 3% (n=143) reported working less (Figure 1 ). Only 27 of those with an adverse change in employment reported retirement; 172 patients (49% of patients no longer working) reported involuntary job loss, such as being laid off or no longer working because of their health and disability.
Patients who experienced an adverse change in employment post-MI were more likely to be women, have diabetes mellitus, hypertension, tobacco use, and were less likely to have a drug-eluting stent placed than patients who continued working as before ( Table 2) . Patients with an adverse change in employment were more likely to have recurrent MI, unplanned revascularization, stroke, and Bleeding Academic Research Consortium 2+ bleeding than patients who were still working ( Table 2) .
In multivariable analysis, the strongest factor associated with adverse change in employment in the 1 year after discharge was the number of readmissions within the first year (odds ratio, 1.20; 95% confidence interval, 1.09-1.32 per event). Other factors significantly associated with adverse change in employment include baseline smoking status, hypertension, and postdischarge bleeding (Table 3) . Notably, factors, such as sex, baseline health status, and recurrent MI, were significant in unadjusted comparisons but did not remain significantly associated with adverse change in employment in the multivariable model.
Outcomes
Patients experiencing an adverse change in employment were more likely to have depression at baseline compared with those experiencing no change (6.5% versus 4.5%; P=0.04); these differences widened at 6 weeks (22.4% versus 19.2%; P=0.1), 6 months Figure 2A ) in part because of observed improvement among patients who resumed work. The difference in depression over time was significant between patients who experienced an adverse change in employment and those who resumed work: P<0.001. Patients not working at baseline, not retired, and who did not resume working at 1 year had significantly higher rates of depression throughout the study period. Patients with an adverse change in employment also had lower self-rated health status (EQ5D VAS) than those not experiencing any adverse change (70. 7 Figure 2B ). Patients not working at baseline, not retired, and who did not resume working at 1 year had significantly poorer EQ5D VAS scores throughout the study period. Change in EQ5D VAS score over time was significant only for patients working at baseline with no adverse change within the next year (P<0.001); these patients experienced improvement in quality of life over time.
At 1 year, patients with adverse changes in employment were more likely to have PHQ2 score >3 suggestive of depression and lower EQ5D VAS scores suggestive of lower quality of life in both unadjusted and adjusted comparisons (Table 4) . No difference was noted in patient-reported medication adherence or in persistence of EBMs prescribed at discharge. However, more patients who had adverse change in employment reported moderate-extreme financial hardship with out of pocket medication costs than those without change in work status after adjustment for clinical and sociodemographic characteristics (Table 4) .
DISCUSSION
This study sheds novel insights into patients' ability to return to work after MI. We found that 1 in 10 patients working at baseline had an adverse change in employment at 1 year; 7% were unable to return to work, and 3% worked less. Almost half of the job losses were described by the patient as involuntary. An adverse change in employment was associated with increased risk of depression, lower self-rated health status, and increased financial hardship associated with affording medications. These findings have important implications for patient-centered care for patients with MI.
A key finding of this analysis is the low rate of adverse change in employment after MI. Improvements in treatments for MI, in addition to causing dramatic reductions in total and age-adjusted mortality after MI, have also resulted in significant improvements in patient functionality after MI. We hypothesize that advances in MI care have also resulted in improvement in patients' ability to resume employment. In comparison with prior literature, we now observe a substantially lower rate of job loss within 1 year after MI. 4, 5, [16] [17] [18] [19] [20] [21] [22] In fact, our study demonstrates the lowest rate of adverse change in employment at 1 year among patients with MI to date (Figure 3 ). These findings thus represent commendable translation of clinical outcomes into patient-centered measures, representing additional crucial protection for patients from the financial hardship associated with medical care. However, this progress must not deter efforts to target patients who are at high risk for job loss with psychosocial and occupational interventions during the initial episode of care for MI. In our study, factors that were associated with the greatest chance of work loss were unplanned hospitalizations, bleeding, hypertension, and smoking status. Finally, similar to prior studies, we demonstrate that patients unemployed at baseline are at risk for poorer outcomes after MI. 3 Depression occurs commonly after MI, and our data suggest that an adverse change in employment is associated with higher rates of depression. Rates of depression increase after MI for all patient groups, however, patients able to resume work actually demonstrate a reduction in rates of depression while those who are unable to resume work see a continuously rising trend in prevalence of depression. Rates of depression in patients unable to resume work begin to approach those who are unemployed and not retired at baseline by 1 year. 3 Furthermore, patients with depression remain at high risk for losing employment even after they return to work. In a recently published nationwide study from Denmark analyzing factors associated with inability to maintain work after, despite resumption of work within a 1-year post-MI, depression was the strongest predictor of subsequent detachment from work. 22 In our analysis, however, although depression was slightly higher at baseline among patients who experienced adverse change in employment (6.5% versus 4.5%; P=0.04), depression was not a significant predictor of adverse change in our adjusted model.
Patients who experience an adverse change in employment also experience poorer quality of life. Selfrated health, in addition to reflecting a poor sense of physical and emotional well being, is also a sensitive marker of adverse clinical outcomes and is associated with increased mortality. 23 Although self-rated health improved steadily for patients, who resumed work (P trend <0.001), it did not do so for patients unemployed at baseline or who were unable to resume work (P trend nonsignificant). These outcomes become increasingly important given their importance to patients and improvements in clinical outcomes, such as mortality.
These associations underscore the importance of this patient-centered outcome and raise several questions. Can we predict or prevent adverse changes in employment? Our data suggest that the factor most strongly associated with job loss was unplanned readmissions. Prevention of post-MI readmission has been the focus of national quality improvement initiatives in recent years. 24 Patients who experienced a bleeding complication also had a higher likelihood of experiencing adverse change in employment. Risk scores to identify patients at high risk of bleeding have been proposed to assist in antiplatelet medication selection and long-term management. 25, 26 Treating depression in patients post-MI has been known to lower depression and improve quality of life, but not cardiovascular outcomes, and it remains unknown whether behavioral or pharmacotherapeutic interventions result in an improved ability to return to work. 27 Unemployment is known to reduce medication adherence, 28 another important factor affecting outcomes in patients after MI. 29 In our study, we examined medication taking in 2 ways: persistence assesses both clinician and patient continuation of EBMs, whereas adherence describes the patient's medication-taking behavior. Although adverse change in employment did not result in a significant difference in medication persistence or adherence in our study, we did find increased financial hardship reported among those whose work status was adversely affected. Financial hardship associated with medications has been shown in prior studies to lead to reduced long-term adherence and worse medical outcomes among post-MI patients. 30 Our study has several limitations. The precise timing of work loss/reduction could not be analyzed. Unmeasured factors may contribute to adverse change in employment. Medication adherence was patient selfreported based on a questionnaire and may be overestimated. Although financial hardship was assessed, specific impact of adverse change in employment on household income could not be examined as ≈43% of patients declined to provide information about income level. Income levels are poorly reported in many observational studies and can be weighted toward both patients with high or low socioeconomic status. 31 Given the observational nature of this study, we cannot make inferences on causality when examining outcomes. Last, we included patients who retired (n=27) into those experiencing as adverse change in employment given that health shocks, such as MI, are associated with early retirement decisions. 32, 33 In conclusion, our study shows the lowest levels of job loss in the context of prior studies of patients with MI . However, almost half of job losses were involuntary. Patients who experience an adverse change in employment are at increased risk of depression, lower quality of life, and increased financial hardship with medication costs compared with those who continue working. Unplanned rehospitalizations and post-MI bleeding are the strongest predictors of adverse change in employment, increasing the impetus to reduce the incidence of these adverse outcomes. These results underscore the need for interventions to address this patient-centered outcome and its health impact.
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